Horizon Pharma to Acquire Hyperion Therapeutics

Horizon Pharma and Hyperion Therapeutics have entered into a definitive agreement under which Horizon Pharma will acquire all of the issued and outstanding shares of Hyperion's common stock for $46.00 per share in cash or approximately $1.1 billion on a fully diluted basis. The per share consideration represents a premium of approximately 35 percent to Hyperion's volume weighted average price for the trailing 60 days. The proposed transaction has been unanimously approved by both companies' boards of directors.

"The Hyperion acquisition will expand and diversify our product portfolio by adding two complementary orphan disease products, Ravicti and Buphenyl, and leverage as well as expand the existing infrastructure of our orphan disease business," said Timothy P. Walbert, chairman, president and CEO, Horizon Pharma. "This transaction will be immediately accretive to adjusted EPS and we expect the contribution of Ravicti and Buphenyl in 2016 will add approximately $100 million to our adjusted EBITDA, including cost synergies contributing greater than $50 million. Additionally, this acquisition further accelerates our near- and long-term sales and adjusted EBITDA growth and provides significant value for both Horizon and Hyperion shareholders."

"During the last 2 years, we have solidified our position in the orphan disease space and made significant progress in bringing life-changing medicines to people with urea cycle disorders," said Donald J. Santel, president and CEO, Hyperion Therapeutics. "I would like to thank my colleagues for their tireless commitment to advancing the clinical development and understanding of Ravicti, Buphenyl and urea cycle disorders. Horizon shares our commitment and I'm confident that the strength of its existing orphan business unit will continue to expand the reach of these important medicines to more patients impacted by these disorders."